<DOC>
	<DOC>NCT00546000</DOC>
	<brief_summary>A multi-center, open-label, Phase IV, unblinded study using Cutivate (fluticasone propionate, 0.05%)lotion and it's possible effects on the HPA axis of infants diagnosed with atopic dermatitis.</brief_summary>
	<brief_title>Cutivate Lotion HPA Axis Pediatric Study</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Subjects are 312 months of age Subjects diagnosed with Atopic Dermatitis (AD) and have â‰¥35% of Body Surface Area Subjects meet protocol specific AD signs and symptom severity score Subjects with conditions effecting the HPA Axis Subjects with clinically significant systemic disease Subjects who require treatment with systemic or topical retinoids during the study Subjects who have been treated with various chronic therapies identified in the protocol Subjects who have received other investigational drug treatment within 30 days prior to study entry</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>